JAZZ

Rating neutralTentativeAI Memo

Jazz Public

As of 2026-08-13/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-13 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Ziihera first-line GEA FDA decision • 2026-08-25

Base target: $255 / p=45% prob

Biggest risk

The deterministic prior remains negative, reflecting expected near- and medium-term downside. Key concerns are the LAGOON-related second-line indication removal, ongoing Xyrem and royalty declines, launch and regulatory execution risk, acquisition integration, and leverage.

Invalidation

Break below $210 or thesis failure.

What would change my mind?

Q2 execution was strong, guidance was raised, and upcoming Ziihera FDA action plus HERIZON-GEA-01 data could expand the oncology growth profile. The stored median analyst target of $285.84 is above the $245.85 anchor, but target-count coverage is unavailable.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-13

Base target

$255

p=45%

Bull target

$300

p=25%

Bear target

$210

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

LAGOON-driven Zepzelca second-line indication removal
Raised 2026 guidance and sustained commercial execution
Q2 execution was strong, guidance was raised, and upcoming Ziihera FDA action plus HERIZON-GEA-01 data could expand the oncology growth profile.

BearKey bullets

As of June 30, 2026, Jazz reported $4.4 billion of long-term debt versus $2.2 billion of cash, cash equivalents and investments.
The Actio transaction commits $820 million upfront and up to $500 million in milestones before clinical and commercial validation of ABS-1230.
The LAGOON outcome is expected to remove Zepzelca's second-line indication; first-line maintenance remains intact but portfolio upside is reduced.

WatchKey bullets

Ziihera first-line GEA FDA decision

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $255 (p=45%)

Target spread vs base: +18% / -18%

Scenario probabilities

Bull Target: $300 (p=25%)Base Target: $255 (p=45%)Bear Target: $210 (p=30%)

Commentary

News buzz is high because of the Q2 earnings release, raised guidance, the August 25 FDA decision, and the Actio acquisition. Net tone is mixed-to-positive: operating results and guidance improved, while LAGOON remains an overhang. No usable social, post-print price-reaction, consensus-surprise, or analyst-revision data was provided, so confidence remains moderate rather than bullish.

As of 2026-08-13 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

LAGOON-driven Zepzelca second-line indication removal
Raised 2026 guidance and sustained commercial execution

Scenarios

Bull Target (Scenario probability)

$300 / p=25% prob

Base Target (Scenario probability)

$255 / p=45% prob

Bear Target (Scenario probability)

$210 / p=30% prob

Analysis 2026-08-13 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-25
Ziihera first-line GEA FDA decision
The company reiterated an August 25, 2026 PDUFA date for zanidatamab combinations in first-line HER2-positive gastroesophageal adenocarcinoma; approval would support a new oncology growth leg, while a delay or rejection would pressure sentiment [#SEC-8K-2026-08-03].
Prob 65.00% • Move 8.00% • Priced-in 60.00%
EVENT2026-11-11
HERIZON-GEA-01 second interim overall-survival data
Top-line results from the second interim overall-survival analysis for the zanidatamab doublet regimen are expected in the third quarter of 2026, creating a meaningful clinical and commercial readout risk/reward [#SEC-8K-2026-08-03].
Prob 50.00% • Move 7.00% • Priced-in 45.00%
EVENT2026-11-11
Actio Biosciences acquisition execution
Jazz entered a merger agreement to acquire Actio for an initial aggregate upfront value of $820 million, plus up to $500 million of contingent milestones tied to ABS-1230 development and sales. The transaction adds pipeline optionality but raises execution and capital-allocation risk [#8-K-2026-08-10].
Prob 50.00% • Move 4.00% • Priced-in 25.00%

Short-term Catalysts

Next few weeks

LAGOON-driven Zepzelca second-line indication removal
2026-11-11
Jazz plans to submit a labeling supplement in the third quarter to remove the second-line Zepzelca indication after the LAGOON result; the first-line maintenance indication is not affected, but the change limits oncology upside [#SEC-8K-2026-08-03].
Prob 85% • Move -5% • Priced-in 75%

Long-term Catalysts

Months to a year

Raised 2026 guidance and sustained commercial execution
2026-12-31
Second-quarter revenue reached $1.208 billion, up 16% year over year, with Xywav, Epidiolex, Zepzelca and Modeyso contributing to growth. Jazz raised 2026 revenue guidance to $4.60-$4.75 billion from $4.25-$4.50 billion [#SEC-8K-2026-08-03].
Prob 72% • Move 6% • Priced-in 70%

Risks

As of June 30, 2026, Jazz reported $4.4 billion of long-term debt versus $2.2 billion of cash, cash equivalents and investments.
The Actio transaction commits $820 million upfront and up to $500 million in milestones before clinical and commercial validation of ABS-1230.
The LAGOON outcome is expected to remove Zepzelca's second-line indication; first-line maintenance remains intact but portfolio upside is reduced.
Xyrem and high-sodium oxybate royalty revenue continued to decline, increasing dependence on newer products and pipeline execution.
Ziihera approval, launch timing, reimbursement and commercial uptake may disappoint despite the August 25 PDUFA date.

Peers

Symbol	Summary
NBIX	Closest operating comparator in the supplied peer set: Neurocrine is a commercial neuroscience-focused biopharma with approved medicines and pipeline programs spanning neurology, psychiatry and endocrinology, overlapping Jazz's neuroscience and epilepsy exposure. It remains a partial rather than full portfolio match.
ASND	Relevant specialty-biopharma comparator with commercial and investigational therapies focused on endocrinology, rare disease and oncology. Its TransCon platform and therapeutic mix are less similar to Jazz's sleep and epilepsy franchises, so relative conclusions should remain directional.
BBIO	Relevant specialty-biopharma comparator with FDA-approved medicines and a development pipeline focused on genetic diseases. It offers a useful read on launch, clinical and execution risk but is a looser therapeutic match than NBIX.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-13

Loading AI feed…

Symbol

Summary

NBIX

Closest operating comparator in the supplied peer set: Neurocrine is a commercial neuroscience-focused biopharma with approved medicines and pipeline programs spanning neurology, psychiatry and endocrinology, overlapping Jazz's neuroscience and epilepsy exposure. It remains a partial rather than full portfolio match.

ASND

Relevant specialty-biopharma comparator with commercial and investigational therapies focused on endocrinology, rare disease and oncology. Its TransCon platform and therapeutic mix are less similar to Jazz's sleep and epilepsy franchises, so relative conclusions should remain directional.

BBIO

Relevant specialty-biopharma comparator with FDA-approved medicines and a development pipeline focused on genetic diseases. It offers a useful read on launch, clinical and execution risk but is a looser therapeutic match than NBIX.